Abstract
Cerebral cavernous malformation (CCM) is a vascular disorder characterized by enlarged, fragile capillary clusters in the central nervous system. While genetic drivers in Western populations are well-documented, data for ethnic Chinese populations remains sparse. This study investigated 95 Taiwanese patients to identify pathogenic variants in the CCM1, CCM2, and CCM3 genes. Through Sanger sequencing and clinical correlation, researchers identified three novel pathogenic variants and observed distinct genotype-phenotype patterns, providing a vital foundation for genetic counseling and diagnostic accuracy in Asian populations.
Introduction
Cerebral Cavernous Malformation (CCM) manifests as "mulberry-like" vascular lesions that can lead to headaches, seizures, and hemorrhagic strokes. The condition is often familial, following an autosomal dominant inheritance pattern involving three primary genes: CCM1 (KRIT1), CCM2 (MGC4607), and CCM3 (PDCD10). Despite the clinical significance of these mutations, genetic research has historically focused on Western cohorts. This study aims to fill the knowledge gap for the Taiwanese population by establishing a localized clinical and genetic database.
Methods and Datasets
The research team conducted a retrospective study of 95 patients at a tertiary medical center in Taiwan. The cohort included individuals with multiple brain lesions or a single lesion with a relevant family history.
Genetic analysis was performed via Sanger sequencing on 41 patients to screen the coding regions of the three primary CCM genes. Variants were identified using sequence alignment tools and classified according to ACMG standards. To verify the novelty of findings, the team cross-referenced global genomic databases including ExAC, gnomAD, and HGMD. Clinical manifestations were correlated with genetic data using susceptibility-weighted imaging (SWI) MRI to assess lesion burden.
Key Results and Genetic Findings
The study successfully identified pathogenic variants in six patients, including three unrelated individuals and three members of a single family. Notably, three "first-of-their-kind" mutations were discovered:
- c.1846delA (CCM1): A deletion in exon 18 leading to a premature stop signal (truncation).
- c.401_402insGCCC (CCM2): An insertion in exon 4 causing a frameshift and early truncation.
- c.485+1G>C (CCM1): A critical splice-site mutation in intron 8 that disrupts proper gene processing.
Clinical Manifestations and Phenotypes
Clinical presentation varied significantly across the cohort. Focal neurological signs, such as weakness or numbness, were the most common initial symptoms (56.8%), followed by seizures (29.5%).
A key insight from the study was the observation of genotype-phenotype correlations. Patients harboring CCM2 variants generally exhibited a milder clinical phenotype, characterized by fewer and smaller brain lesions, compared to those with CCM1 mutations. Furthermore, the study highlighted significant clinical heterogeneity; even family members with identical mutations displayed varying degrees of severity, suggesting the influence of environmental or secondary genetic modifiers.
Discussion and Future Directions
The detection rate for genetic variants in this Taiwanese familial cohort (approx. 7.6%) was notably lower than the 70-90% typically reported in Western studies. This discrepancy suggests that the Taiwanese population may have unique genetic drivers yet to be identified, or that standard Sanger sequencing is insufficient to detect larger structural genomic rearrangements.
Future research should incorporate Multiplex Ligation-dependent Probe Amplification (MLPA) to identify large-scale deletions or duplications. Additionally, functional validation of identified "Variants of Uncertain Significance" (VUS) using cell models will be crucial to definitively link these genetic tweaks to the vascular malformations observed in patients.
Summary updated